April 1, 2013
By:
Reflector
The European Union's attempt to update its transparency rules sparks new debate.
|
|
March 1, 2013
By:
Rachel Lee, Martin Reeves
Chinese policies are to pose new opportunities and challenges for Big Pharma companies active in the country.
|
March 1, 2013
By:
Reflector
European Commision blocks the authorization of a life-saving liver drug outside of France.
|
|
February 1, 2013
By:
Julian Upton
After a decade of strife, the dialogue between industry and government appears to have entered a positive new phase. Julian Upton reports.
|
January 1, 2013
By:
William Looney
Promoting the merits of private-sector drug innovation is no easy task—just ask the UK's Office of Health Economics, with a record 50 years of engagement around the hard policy questions that ultimately drive success in the pharmaceutical marketplace.
|
December 1, 2012
By:
William Looney
Europe's chief regulator charts a strategy from many moving parts. Dr Guido Rasi talks to Pharm Exec's William Looney.
|
December 1, 2012
At two years and counting, what's the secret of success in negotiating pricing under the new AMNOG legislation?
|
November 1, 2012
By:
William Looney
Spain's leading business school, IESE, organized an expert conference on October 2-3 to address two simple questions. First, how can providers and payers work together to generate more value from existing resources? Second, what must be done to ensure the system continues to create value in the first place?
|
November 1, 2012
By:
Reflector
For the second time in recent memory, a top European regulator leaves office abruptly and under a cloud of suspicion.
|
|
PharmExec Blog
Follow Us
RSS
Bookstore
